Skip to main content

Advertisement

SpringerLink
Log in

Quantitative assessment of the association between TP53 Arg72Pro polymorphism and risk of glioma

  • Research Article
  • Published:
Tumor Biology

Abstract

Many studies have investigated on the association between TP53 Arg72Pro polymorphism and risk of glioma, but the impact of TP53 Arg72Pro polymorphism on glioma risk is unclear owing to the obvious inconsistence among those studies. To shed light on these inconclusive findings and get a quantitative assessment of the association between the TP53 Arg72Pro polymorphism and risk of glioma, we conducted a meta-analysis of eligible studies. We searched PubMed and Embase databases for studies investigating on the association between the TP53 Arg72Pro polymorphism and risk of glioma. The pooled odds ratios (OR) with their 95 % confidence intervals (95 % CI) was calculated to assess the association between the TP53 Arg72Pro polymorphism and risk of glioma. A total of 12 studies were finally included into the meta-analysis. Meta-analysis of the 12 studies showed that TP53 Arg72Pro polymorphism was not associated with the risk of glioma (ORPro vs. Arg = 1.07, 95 % CI 0.93∼1.22; ORProPro vs. ArgArg = 1.02, 95 % CI 0.85∼1.22; ORProPro/ArgPro vs. ArgArg = 1.06, 95 % CI 0.85∼1.34; and ORProPro vs. ArgArg/ArgPro = 1.07, 95 % CI 0.91∼1.27). Subgroup analyses by ethnicity further identified that TP53 Arg72Pro polymorphism was not associated with the risk of glioma in Caucasians. However, there was a mild association between the TP53 Arg72Pro polymorphism and risk of glioma in Asians (ORProPro vs. ArgArg/ArgPro = 1.42, 95 % CI 1.00∼2.02). Thus, there is limited evidence for the association between the TP53 Arg72Pro polymorphism and risk of glioma, and more studies are needed to provide a more comprehensive assessment of the association in Asians.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Chen J, McKay RM, Parada LF. Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell. 2012;149:36–47.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Goodenberger ML, Jenkins RB. Genetics of adult glioma. Cancer Genet. 2012;205:613–21.

    Article  CAS  PubMed  Google Scholar 

  3. Wang Y, Jiang T. Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett. 2013;331:139–46.

    Article  CAS  PubMed  Google Scholar 

  4. Marumoto T, Saya H. Molecular biology of glioma. Adv Exp Med Biol. 2012;746:2–11.

    Article  CAS  PubMed  Google Scholar 

  5. Hu M, Shi H, Xu Z, Liu W. Association between epidermal growth factor gene rs4444903 polymorphism and risk of glioma. Tumour Biol. 2013;34:1879–85.

    Article  CAS  PubMed  Google Scholar 

  6. Zhang H, Liu H, Knauss JL. Associations between three XRCC1 polymorphisms and glioma risk: a meta-analysis. Tumour Biol 2013; doi: 10.1007/s13277-013-0865-1

  7. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science. 2005;309:1732–5.

    Article  CAS  PubMed  Google Scholar 

  8. Vousden KH, Lane DP. P53 in health and disease. Nat Rev Mol Cell Biol. 2007;8:275–83.

    Article  CAS  PubMed  Google Scholar 

  9. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789–99.

    Article  CAS  PubMed  Google Scholar 

  10. Whibley C, Pharoah PD, Hollstein M. P53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95–107.

    Article  CAS  PubMed  Google Scholar 

  11. Dumont P, Leu JI, Della Pietra 3rd AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357–65.

    Article  CAS  PubMed  Google Scholar 

  12. Wang LE, Bondy ML, Shen H, El-Zein R, Aldape K, Cao Y, et al. Polymorphisms of DNA repair genes and risk of glioma. Cancer Res. 2004;64:5560–3.

    Article  CAS  PubMed  Google Scholar 

  13. Malmer B, Feychting M, Lonn S, Ahlbom A, Henriksson R. P53 genotypes and risk of glioma and meningioma. Cancer Epidemiol Biomarkers Prev. 2005;14:2220–3.

    Article  CAS  PubMed  Google Scholar 

  14. Parhar P, Ezer R, Shao Y, Allen JC, Miller DC, Newcomb EW. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Brain Res Mol Brain Res. 2005;137:98–103.

    Article  CAS  PubMed  Google Scholar 

  15. Idbaih A, Boisselier B, Marie Y, El Hallani S, Sanson M, Criniere E, et al. Tp53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors. Cancer Genet Cytogenet. 2007;177:103–7.

    Article  CAS  PubMed  Google Scholar 

  16. Malmer BS, Feychting M, Lonn S, Lindstrom S, Gronberg H, Ahlbom A, et al. Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J Neurooncol. 2007;82:229–37.

    Article  CAS  PubMed  Google Scholar 

  17. El Hallani S, Ducray F, Idbaih A, Marie Y, Boisselier B, Colin C, et al. Tp53 codon 72 polymorphism is associated with age at onset of glioblastoma. Neurology. 2009;72:332–6.

    Article  PubMed  Google Scholar 

  18. Carvalho RM, Pinto GR, Yoshioka FK, Lima PD, Souza CR, Guimaraes AC, et al. Prognostic value of the TP53 Arg72Pro single-nucleotide polymorphism and susceptibility to medulloblastoma in a cohort of Brazilian patients. J Neurooncol. 2012;110:49–57.

    Article  CAS  PubMed  Google Scholar 

  19. Jin T, Zhang J, Li G, Li S, Yang B, Chen C, et al. TP53 and RPA3 gene variations were associated with risk of glioma in a Chinese Han population. Cancer Biother Radiopharm. 2013;28:248–53.

    Article  CAS  PubMed  Google Scholar 

  20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

    Article  PubMed  Google Scholar 

  21. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.

    CAS  PubMed  Google Scholar 

  22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

    Article  CAS  PubMed  Google Scholar 

  23. Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469.

    Article  CAS  PubMed  Google Scholar 

  24. Rajaraman P, Wang SS, Rothman N, Brown MM, Black PM, Fine HA, et al. Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev. 2007;16:1655–61.

    Article  CAS  PubMed  Google Scholar 

  25. Lima-Ramos V, Pacheco-Figueiredo L, Costa S, Pardal F, Silva A, Amorim J, et al. Tp53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas. Cancer Genet Cytogenet. 2008;180:14–9.

    Article  CAS  PubMed  Google Scholar 

  26. Pinto GR, Yoshioka FK, Silva RL, Clara CA, Santos MJ, Almeida JR, et al. Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms and the susceptibility to gliomas in individuals from Southeast Brazil. Genet Mol Res. 2008;7:207–16.

    Article  CAS  PubMed  Google Scholar 

  27. Jha P, Pathak P, Chosdol K, Suri V, Sharma MC, Kumar G, et al. TP53 polymorphisms in gliomas from Indian patients: study of codon 72 genotype, rs1642785, rs1800370 and 16 base pair insertion in intron-3. Exp Mol Pathol. 2011;90:167–72.

    Article  CAS  PubMed  Google Scholar 

  28. Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case–control studies. Int J Cancer. 2011;129:920–30.

    Article  CAS  PubMed  Google Scholar 

  29. Zou YF, Wang F, Feng XL. TP53 Arg72Pro polymorphism may have little involvement in the pathogenesis of skin cancer in Caucasians. J Invest Dermatol. 2011;131:781–2.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Neurology, Jinan Central Hospital Affiliated to Shandong University, Jinan, 250013, China

    Feng Zhang, Danni Li, Yanshuang Li, Jinbo Sun & Xiaohong Li

  2. Department of Health, Jinan Central Hospital Affiliated to Shandong University, Jinan, 250013, China

    Haixia Li

  3. Department of Neurology, Second Artillery Corps General Hospital, Beijing, 100088, China

    Xianfeng Li

Authors
  1. Feng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Danni Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yanshuang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Haixia Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jinbo Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xianfeng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiaohong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaohong Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, F., Li, D., Li, Y. et al. Quantitative assessment of the association between TP53 Arg72Pro polymorphism and risk of glioma. Tumor Biol. 35, 747–751 (2014). https://doi.org/10.1007/s13277-013-1101-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1101-8

Keywords

Search

Navigation